HEC Pharma
HEC Pharm, listed on the Hong Kong Stock Exchange, is a fully integrated pharmaceutical company with a strong focus on infectious diseases, oncology, metabolic disorders, and other chronic conditions. The company has three innovative drugs approved and a robust pipeline of over 40 candidates in various stages of development. Established in 2005, HEC’s R&D center in Guangdong, China, employs more than 1,000 scientists and provides end-to-end drug discovery and development capabilities. Its technology platforms span all major drug modalities, including small molecules, oligonucleotides, peptides, antibodies, antibody-drug conjugates (ADCs), and cell therapies.
